• {%brandMenuItems%}
    • {%itemName%} {%arrowSpan%}
    • {%itemName%} {%arrowSpan%}
    • {%selfProduct%}
      • {%languages%}
    • This website is for UK Healthcare Professionals only

      DUODOPA Enables Your Patients to Continue Their Gold Standard Treatment

      For levodopa-responsive patients with complex/advanced Parkinson’s


      In a study, DUODOPA provided predictability of ‘ON’ time and ‘OFF’ time2

      In a 54-week safety study, patients with severe motor fluctuations on DUODOPA had a significant increase in 'ON' time without troublesome dyskinesia and a significant decrease in 'OFF' time compared with baseline (both p<0.001), which was sustained throughout the study.2

      Patient video: Richard's story

      "I’d arranged a trip… I was able to go with no interruptions from the drug… there were no tremors, no freezing, I could walk properly."
      Richard, 2017. Duodopa patient


      In a study, DUODOPA had a greater effect on total non-motor symptom score than apomorphine3*

      In a 6-month study comparing the effects of DUODOPA and apomorphine, increase from baseline in non-motor symptom scale (NMSS) score was:3

      • DUODOPA +0.83
      • Apomorphine +0.53
      • Both treatments had similar efficacy for motor scores and HRQoL

      Significant results:3

      • Duodopa: Sleep/fatigue (p=0.017);* Gastrointestinal (p=0.004);*  Urinary (p=0.0001);*  Sexual function (p=0.001)*
      • Apomorphine: Mood/apathy (p=0.03)*

      In a study, benefits in non-motor symptoms were sustained over a period of two years with DUODOPA4

      In a 24-month registry study evaluating safety and efficacy of Duodopa, significant and sustained improvements in motor fluctuations and associated non-motor symptoms were observed (p<0.001)†4

      Particularly in:4

      • Sleep/fatigue (p<0.001) 
      • Mood/cognition (p=0.004)
      • Gastrointestinal symptoms (p<0.001)

      Improvement measured by reduction from baseline in the mean non-motor symptoms scale (NMSS) scores.

      Patient video: Steve's story

      "Because there were 2 years when I couldn’t do anything, I’m overcompensating, by doing things 7 days a week."
      Steve, 2017. Duodopa patient


      Dosing is reliable with the smooth delivery of DUODOPA1


      Duodopa offers a reliable solution around the problem of delayed gastric emptying1


      The consistent delivery of DUODOPA smooths out any peaks or troughs in plasma concentration1


      Dosing can be individually optimised to suit the patient, over a 16-hour period1


      In a study, DUODOPA provided significant and sustained reductions in dyskinesia5

      In a 12-week study, advanced PD patients were randomised to receive either OMT (n=33) or DUODOPA (n=28).5

      Patients who received DUODOPA had sustained and significant improvements in UDysRS total scores through Week 12 compared to OMT (p<0.001).5

      At Week 12, compared to OMT, patients treated with DUODOPA experienced5:

      • 3.27 hours more ‘ON’ time without troublesome dyskinesia (3.15 hours with DUODOPA vs -0.12 hours with OMT; p=0.0001)

      • 2.35 hours less ‘OFF’ time (-2.17 hours with DUODOPA vs 0.18 hours with OMT; p=0.0002)

      Patient video: Grace's story

      "We used to have a wheelchair in the house and Brian used to push me around in the wheelchair for the times I couldn’t walk. But I always had a pusher… "
      Grace, 2017. Duodopa patient

      Safety & Tolerability

      DUODOPA has a well-understood safety profile2

      An open-label study shows DUODOPA offers a well-understood adverse event profile2

      • For the majority of patients adverse events are mild (19%) or moderate (44%) and transient2
      • Low withdrawal rate (8%) due to adverse events, most commonly due to complication of insertion of device2

      For more detailed safety information, please refer to the Summary of Product Characteristics (SmPC).

      I want to receive more information about DUODOPA


      1. Nyholm D, et al. AAPS J 2013;15:316–23.
      2. Fernandez HH, et al. Mov Disord 2015;30:500–9.
      3. Martinez-Martin P, et al. Mov Dis 2015;30:510–6.
      4. Antonini A, et al. Parkinsonism Relat Disord 2017;45:13–20.
      5. Alvarez EF, et al. Presented at the MDS Virtual Congress, 12–16 September 2020:867.

      Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk.

      Adverse events should also be reported to AbbVie on GBPV@abbvie.com 


       UK-DUOD-210079. Date of preparation: May 2021.